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Abstract
Objective Pituitary adenomas are benign neoplasms that
display invasive behavior—a characteristic traditionally
associated with malignancy—through an ill-defined
mechanism. The role of angiogenesis-related molecules in
this pathological condition remains perplexing. Our pur-
pose is to assess the impact of endocan (endothelial cell
specific molecule-1, ESM-1), CD34 and CD105 on pitu-
itary adenoma invasion.
Methods In this study, immunohistochemical analyses for
endocan, CD34 and CD105 were performed on paraffin-
embedded samples of 66 pituitary adenomas, five normal
pituitaries, and five primary hepatic carcinomas. Knosp
tumor grades based on magnetic resonance imaging coro-
nal scanning were used to assess the invasiveness of each
sample. The associations between endocan expression,
CD34/CD105-positive microvessel densities (MVDs), and
Knosp tumor invasion grades were evaluated.
Results These results showed that endocan protein
expression in tumor cells (TCs) was higher than that in
endothelial cells (ECs) and strongly correlated with Knosp
grades (P\ 0.001, Spearman’s r = 0.616). Moreover,
while endocan-positive TCs localized around the blood
vessels in adenomas with higher Knosp grades, no signif-
icant association was found between CD34/CD105-MVDs
and Knosp grades (CD34: P = 0.256, r = 0.142; CD105:
P = 0.183, r = 0.166). Normal pituitary seemed to exhibit
lower endocan expression and contained more CD34/
CD105-MVDs than pituitary adenomas.
Conclusion Endocan expresses in both TCs and ECs of
pituitary adenoma. Endocan overexpression in TCs more
accurately reflects invasiveness compared to that of CD34/
CD105-MVDs and that angiogenesis may not be the pri-
mary driver of endocan-medicated pituitary adenoma
invasion.
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Introduction
Pituitary adenomas arise from intracranial adenohypophy-
seal cells and have a prevalence of 2.87–3.90 per 100,000
individuals in the general population [7, 23]. While histo-
logically benign, approximately 35 % of pituitary adeno-
mas exhibit aggressive or malignant growth patterns that
can result in recurrence after initial surgical treatment [20].
Defined as invasive pituitary adenomas (IPA), they are
inclined to invade cavernous sinus, the dura mater, bone,
and even the central nervous system [2, 15]. Clinically,
Knosp grades are based on the extent of invasion into the
carotid artery and are a widely used measure of tumor
aggression [10].
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Angiogenesis plays an important role in a variety of
tumor initiation and progression [6, 14, 17]. But its role in
pituitary adenomas remains extremely controversial [2, 5,
14, 16, 18, 22, 24]. In previous investigations, several
angiogenic factors or biomarkers—including CD34, endo-
can, and vascular endothelial growth factor (VEGF)—were
found to be widely expressed in pituitary adenomas and
associated with an aggressive phenotype [16, 18, 19]. In
contrast, an increasing number of studies demonstrate that
pituitary adenomas have lower angiogenesis and
microvessel densities (MVDs) than normal pituitary tis-
sues. Therefore, invasive pituitary adenomas may develop
through a non-angiogenic process, which might explain
why the majority of pituitary adenomas are less angiogenic
than other tumor types [2, 5, 14, 22, 24].
Recently, expression of an intercellular signaling protein
present in vascular endothelial cells, termed endocan (en-
dothelial cell-specific molecule-1, ESM-1), was identified
to be pivotal for tumor progression and invasion [1, 3, 16,
21, 27]. Endocan is exclusively expressed by CD34-posi-
tive vascular endothelial cells in pituitary adenomas, where
it strongly correlates with an invasive phenotype [3, 16].
Although endocan overexpression by non-tumorigenic
endothelial cells promotes tumor progression, accumulat-
ing evidence demonstrates that endocan may be of non-
endothelial origin [3, 21]. Moreover, endocan expression
was detected in several glioblastoma or renal carcinoma
cell lines and primary human adipocytes [12, 17, 26]. but
was rarely found in endothelial cells of normal pituitary
tissues with the exception of a few isolated endocrine cells
[3].
In the present study, we examined the expression of
endocan, the pan-endothelial marker CD34, and the acti-
vated endothelial marker CD105 in pituitary adenomas and
normal pituitary glands using semi-quantitative immuno-
histochemical staining. The purpose of this study was to
clarify the expression pattern of endocan in pituitary ade-
nomas and explore the association between endocan
expression, CD34/CD105-MVD, and radiological Knosp




Tumor samples were collected from a total of 127 patients
with pituitary adenomas, who underwent transsphenoidal
or craniotomy surgery (by Dabiao Zhou and Shusen Guan)
at Beijing Tiantan Hospital between 2012 and 2014. All
authors had obtained access to identifying information
during data collection. Patients younger than 18 years old,
with recurrent tumors, microadenomas (diameter\1 cm),
or those who received medicine treatment or radiotherapy
prior to surgical intervention were excluded from the study,
leaving a total enrollment of 66 patients. The patient
population consisted of 37 males and 29 females with an
average age of 43.9 years old (range 18–68 years). Pre-
operative examination consisted of endocrinology blood
work, MRI with enhancement, and CT scans with bone
window.
Five normal pituitary glands from deeded bodies with-
out pituitary and endocrine disease and five primary hep-
atic carcinoma tissue samples were obtained from the
Chinese Academy of Medical Sciences (CAMS) and Bei-
jing Youan Hospital, respectively.
Immunohistochemical staining
All tissues were fixed in 10 % formaldehyde for 24 h,
embedded in paraffin and cut into 4-lm-thick sections.
After incubation in a thermo tank for 30 min, the sections
were deparaffinized and subjected to immunohistochem-
istry. The slides were then rinsed in distilled water for
2 min and treated with 3 % hydrogen peroxide for 12 min
to suppress endogenous peroxidases. Next, the slides were
rinsed with distilled water for 5 min, washed in PBS
(phosphate buffer saline) three times for 5 min each,
soaked in a citrate buffer (0.01 M, pH 6.0), heated in a
microwave oven, naturally cooled to room temperature,
washed once in distilled water and washed in PBS twice for
5 min each for antigen revival. After a 30 min incubation
in PBS containing 2 % BSA, the slides were stained with
primary antibodies—including mouse monoclonal endocan
(ab56914, 1:1000; Abcam, Cambridge, MA, USA), mouse
monoclonal CD34 (sc-19621, 1:250; Santa Cruz, Dallas,
TX, USA), and goat monoclonal CD105 (sc-23838, 1:250;
Santa Cruz)—and incubated overnight at 4 C. The next
day, the slides were rewarmed for 30 min at room tem-
perature, washed twice in PBS for 5 min each, incubated in
polymer helper (pv9002; Beijing Zhongshan Golden bridge
Biotechnology, Beijing, China) for 20 min at room tem-
perature, washed again in PBS twice for 5 min each, and
then allowed to react with the corresponding secondary
antibody solution for 20 min at room temperature. After
two washes in PBS for 5 min each time, the slide were
visualized using 0.05 % diaminobenzedinetetrahydrochlo-
ride (DAB, ZLI-9018; Beijing Zhongshan Golden Bridge
Biotechnology, Beijing, China), washed in tap water,
rinsed in distilled water for 5 min, incubated with hema-
toxylin, washed in tap water, rinsed in 75 % alcohol and
0.5 % hydrochloric acid, dehydrated, cleared, and then
mounted with neutral gum.
Pituitary (2016) 19:194–201 195
123
Evaluation of the cytoplasm staining reaction
and determination of the MVD
For evaluation of endocan, the immunoreactive score (IRS)
was obtained by multiplying the staining intensity (SI:
0 = negative; 1 = weak; 2 = intermediate; 3 = strong)
and percentage of positive tumor/endothelial cells (PPC:
0 = 0 %; 1 = 1–10 %; 2 = 11–50 %, 3 = 51–80 %;
4 =[80 %) as established previously 24. IRS =
SI 9 PPC. Five high power fields (HPFs) (4009) were
randomly selected from each slide for IRS calculation. To
determine the MVD, tissue sections stained with CD105
and CD34 were examined using an Olympus BX61 light
microscope. According to the methods exposed by Weid-
ner previously [25]. The sections were firstly examined at
1009 magnification for the location rich of blood vessels.
Then, pictures of five different fields were taken at 2009
magnification. Finally, the number of blood vessels in each
picture was counted independently by two researchers.
Every single cell and cell cluster stained were assessed as a
blood vessel, regardless of whether the structure of vas-
cular lumen was observed. Every 40 microns of one large
lumen was recorded as one blood vessel. The average value
of five fields was recorded as the MVD score [25].
Radiological assessment for cavernous sinus
invasion
The intercarotid lines described by Knosp et al. on mag-
netic resonance imaging (MRI) coronal scanning were
used to assess cavernous sinus invasion for the 66 tumors.
Five grades are used to represent the extent of tumor
invasion from Grade 0 to 4. According to the Knosp MRI
grading system, Grade 3, Grade 4, and[80 % of Grade 2
pituitary adenomas were considered to be invasive [10].
Statistical analysis
Statistical analysis was performed in SPSS 16.0, JMP 10.0,
and Graphpad 6.04. Rank sum tests were used to estimate
the difference of IRS between tumor cells and endothelial
cells. Spearman’s correlation was used to assess the rela-
tionships between endocan IRS, CD34/CD105-MVD, and
Knosp tumor grades. Pearson correlation was used to assess
the relationships between endocan IRS and CD34/CD105-
MVD. Statistical significance was defined as P\ 0.05.
Ethical permission
The current study was approved by the Clinical Research
Ethics Committee of CAMS (Project No: 009-2014). All
patient records were anonymized prior to analysis and were
approved for use by Clinical Research Ethics Committee of
Beijing Tiantan Hospital (Project No: KY2014-021-02).
Results
Patient population and immunohistochemical data
Of the 66 pituitary adenomas in the present study, 31
(47.0 %) were functioning adenomas [15 prolactinomas,
five growth hormone (GH), one adrenocorticotrophic hor-
mone (ACTH) adenoma, ten mixed adenomas], 35
(53.0 %) were non-functioning ademomas (26 null cell
adenomas and 9 gonadotrophic adenomas). Table 1 sum-
marizes the distribution of Knosp grades across the patient
population and the corresponding endocan expression IRS
in tumor/endothelial cells, as well as CD34/CD105-posi-
tive MVD. Five pituitary tissues were immunostained for
endocan and CD34/CD105 as controls.
Endocan immunoreactivity in tumor cells
and vascular endothelial cells of pituitary adenomas
Immunohistochemical staining of pituitary adenoma tissues
revealed that endocan was mostly expressed specifically in
tumor cells and a few vascular endothelial cells (Fig. 1a–e).
Quantitatively, endocan expression in tumor cells had a
significantly higher immunoreactivity score than that of
vascular endothelial cells (P\ 0.01, Table 1). In Knosp
Grade 3 and 4 tumors, endocan was often detected in the
cytoplasm of tumor cells surrounding the blood vessels with
a high polarity toward the vessel lumen side (Fig. 2a). In the
normal pituitary gland, endocan was weakly expressed in
endocrine cells and a few vascular endothelial cells
(Fig. 2b), whereas it was mainly expressed in the vascular
endothelial cells in cancer nests and adjacent tumor cells in
primary hepatic carcinoma samples (Fig. 2c).
Correlation between endocan expression and Knosp
tumor grades
The distribution of the IRS (tumor and endothelial cells) in
pituitary adenomas according to Knosp tumor grades are
shown in Fig. 3. The mean IRS for endocan with respect to
each Knosp grade was 4.8 (ranging from 1 to 12) for Grade
0, 4.1 (1–6) for Grade 1, 6.8 (1–12) for Grade 2, 9.2 (4–12)
for Grade 3, and 10.2 (6–12) for Grade 4 (Table 1).
Spearman’s rank correlation test demonstrated a significant
and positive correlation of endocan expression in tumor
cells with Knosp tumor grade (P\ 0.001, Spearman’s
r = 0.616). In comparison, endocan expression in
endothelial cells was unrelated to Knosp tumor grades
(P[ 0.05, Spearman’s r = 0.208; Linear regression,
196 Pituitary (2016) 19:194–201
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r2 = 0.3679 (Knosp and TCs), r2 = 0.0433 (Knosp and
ECs).
CD34 and CD105 expression in pituitary adenomas
and normal glands
CD34 and CD105 immunoreactivity was exclusively
observed in vessel endothelial cells. Representative
examples of vessels stained for CD34 and CD105 in
pituitary adenomas and normal pituitary glands are shown
in Figs. 4 and 5. Interestingly, while MVDs in the pituitary
adenomas with high endocan expression were slightly
higher than those observed in tumors with low expression,
MVDs were the most distinct in the normal pituitary gland
(Table 1).
Fig. 1 Coronal MR images with enhancement and endocan expres-
sion in the Knosp Grade 4 (a, b), 2 (c, d), and 0 (e, f) pituitary
adenomas. In Grade 4 pituitary adenoma, ICA were entirely encased
by tumor (a) and endocan was expressed in the cytoplasm of tumor
cells and a few endothelial cells (b; IRS-TC = 12, IRS-EC = 1).
Endocan expression was weaker in Grade 2 tumor which crossed the
ICA center line but not the tangent line temporal side of blood vessel
(c). Although endocan was expressed in tumor cells and endothelial
cells, some cells were scattered in a negative expression (d; IRS-
TC = 8, IRS-EC = 6). The Knosp Grade 0 adenoma did not cross the
tangent line nasal side of blood vessel (e) and exhibited lower
endocan reactivity (f; IRS-TC = 1, IRS-EC = 1). Magnification,
9400
Table 1 Knosp tumor grades,
mean endocan IRS, and mean
MVD score for CD34/CD105-
positive capillaries in 66
pituitary adenomas
Knosp grade No. Mean IRS-TCs Mean IRS-ECs MVD
CD34 (Mean ± SD) CD105 (Mean ± SD)
0 13 4.8 1.8 44.3 ± 30.1 40.4 ± 23.4
1 10 4.1 4.4 46.0 ± 22.2 44.7 ± 18.1
2 15 6.8 4.9 50.4 ± 30.1 51.6 ± 28.4
3 13 9.2 4.2 60.8 ± 30.6 55.3 ± 31.9
4 15 10.2 4.3 48.3 ± 17.9 47.6 ± 16.7
Total 66 7.2* 3.9 50.1 ± 26.6 48.2 ± 24.4
Pituitary 5 5.2 3.0 72.1 ± 9.7 136.8 ± 35.4
TCs tumor cells, ECs endothelial cells
* In 66 pituitary adenomas, tumor cells IRS was significant higher than vascular endothelial cell IRS
(P\ 0.001)
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Correlation between CD34/CD105-MVDs
and Knosp tumor grades
The mean positive MVD based on CD34/CD105
immunostaining under 2009 magnifications for each
Knosp grade was shown in Table 1. No significant asso-
ciation was observed between Knosp tumor grades and the
presence of CD34- or CD105-positive MVDs (CD34:
P = 0.256, Spearman’s r = 0.142; CD105: P = 0.183,
Spearman’s r = 0.166) (Table 1).
Correlation between tumor cell endocan expression
and CD34/CD105-MVDs
Pearson’s rank correlation testing demonstrated a signifi-
cant, albeit weak, correlation between CD34/CD105-
MVDs and endocan expression in tumor cells (CD34:
P = 0.034, Pearson’s r = 0.262; CD105: P\ 0.010,
Pearson’s r = 0.316).
Fig. 2 Endocan expression in pituitary adenoma, normal pituitary
and primary hepatic carcinoma. Endocan was overexpressed in tumor
cells and a few vascular endothelial cells in Grade 4 pituitary
adenomas. Tumor cells surrounded the blood vessel intensely, with
endocan characteristically distributed in the cytoplasm and polarized
towards the blood vessel lumen (a). Endocan was weakly expressed in
endocrine cells and a few vascular endothelial cells in the normal
pituitary gland (b). In primary hepatic carcinoma, endocan was over-
expressed in vascular endothelial cells within the cancer nests and
adjacent tumor cells (c). Magnification: A, 9400; B, 9100; C, 9400
Fig. 3 Distribution of endocan
IRS in tumor cells (IRS-TCs)
and endothelial cells (IRS-ECs)
of five Knosp tumor grades
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Discussion
Pituitary adenomas with clinically aggressive phenotypes
carry a lower ratio of total resection and higher recurrence
rate after surgical intervention. Much effort has focused on
the identification of key molecules that regulate tumor
growth and invasion. Recently, endocan (endothelial cell-
specific molecule-1, ESM-1) secreted by endothelial cells
was found to associate with tumor development and pro-
gression [1, 3, 16, 21, 27].
Endocan is a soluble, 50-kDa proteoglycan comprising a
core protein that consists of 165 amino acids and a single
dermatan sulfate chain. Endocan was originally cloned
from a human endothelial cell cDNA library [11]. As a
biomarker of neovascularization, increased endocan
expression is often used as an indicator of tumor progres-
sion and metastasis in malignances such as glioblastoma,
non-small cell lung cancer, renal cell carcinoma, hepato-
cellular carcinoma and others [8, 9, 12, 17]. In addition,
endocan is also found to be strongly associated with tumor
invasion in benign pituitary adenomas [3, 16]. Like other
proteoglycans, the biological characteristics of endocan
depend upon the binding activity through either the core
protein or dermatan sulfate chain. In an early study in a




according to Knosp tumor
grades. Correlations between
endocan immunoreactive score
(IRS) in TCs/ECs and Knosp
tumor grades (a P\ 0.001,
Spearman’s r = 0.616;
b P[ 0.05, Spearman’s
r = 0.208)
Fig. 5 Tissues from representative IRS-TC = 12 (a, d) and IRS-
TC = 1 (b, e) pituitary adenomas and from a normal pituitary
gland(c, f) for CD34 (a–c) and CD105 (d–f) immunostaining. MVDs
in panels a and d are not more noticeable than those in b and e,
whereas those in the normal pituitary gland are the most pronounced
in panels c and f. Magnification, 9200
Pituitary (2016) 19:194–201 199
123
xenotransplantation mouse model of colon cancer, endocan
overexpression in HEK293 and HT29 cells found to
enhance tumorigenesis, validating endocan as a protu-
morigenic factor [3].
Here, a total of 66 pituitary adenomas, five normal
pituitary glands, and five primary hepatic carcinoma sam-
ples were examined for endocan expression by immuno-
histochemistry. We found that endocan expression—
especially that observed in tumor cells—was strongly
associated with Knosp tumor grades. While both endothe-
lial and tumor cells expressed endocan in pituitary adeno-
mas, there were many endocan-negative endothelial cells
in both invasive and non-invasive tumors. Our results are
similar to the findings in cultured cell lines in which
endocan was found to be expressed in tumor cells, such as
human glioblastomas and renal carcinoma, as well as
human adipocytes [12, 17, 26]. These endocan-positive
cells are of non-endothelial origin. In hepatocellular car-
cinoma tissues, Kang et al. [9] observed strong ESM-1
expression in the cytoplasm of tumor cells compared to
normal tissues by immunofluorescent staining. Moreover,
in a study of 159 gastric carcinomas, ESM-1 protein was
detected in the tumor epithelium in more than half of
samples, particularly in the tumor cell plasma membrane
[13]. Using immunohistochemistry, we first revealed that
endocan is mainly synthesized and secreted by tumor cells
in pituitary adenomas. Additionally, endocan-positive
tumor cells were found to adhere to the blood vessels
intensely in tumors with higher Knosp grades. Collectively,
we theorize that increased endocan expression in tumor
epithelial cells, rather than the vascular endothelial cells,
may be an essential step in tumor formation and growth,
and is therefore associated with aggressive behavior.
Angiogenesis is considered to be critical for malignant
tumor progression, but this notion has raised much con-
troversy in the analysis of pituitary tumors [2, 14, 16, 18,
24]. A number of studies revealed that pituitary adenomas
have lower MVDs than normal pituitary tissues, and pitu-
itary adenomas commonly display less angiogenesis than
other tumor types [2, 5, 14, 22, 24]. Consistent with this
fact, we also found that the mean positive MVDs of CD34
and CD105 in the five normal pituitary glands were
markedly higher than those in pituitary adenomas,
regardless of the Knosp tumor grade. It was thus speculated
by our groups that lower vascularization in pituitary ade-
nomas may be basis for the lower occurrence of tumor
malignant transformation or metastasis, although some
adenomas are clinically invasive.
In the fluorescence analysis of 70 pituitary adenomas,
Matano et al. indicated that expression was detected in all
vascular endothelial cells, but in very few tumor
parenchymal cells; whereas endocan localized with more
than 90 % of CD34-positive endothelial cells in the
samples examined [16]. Thus, they concluded that a sig-
nificant relationship exists between endocan expression,
Knosp tumor grades, and CD34-positive vessels of pitu-
itary adenomas; however, we were unable to find any
significant association between the presence of CD34- or
CD105-MVDs and Knosp tumor grades. Rather, our results
show that endocan expression in tumor cells more accu-
rately reflects the invasiveness when compared to that of
CD34/CD105-positive MVDs. We believe that this was not
a sequence of different immunostaining methods or tech-
niques. We support the statement in a review article that
endocan is a protumorigenic molecule when overexpressed
in tumor epithelial cells [4].
There are limitations in the present study. A given
tumor’s Knosp grade may be dependent on the time of
imaging (i.e., there is a wide variability of IRS scores from
0 to 12 for Knosp Grade 0 tumors). The pathophysiological
significance of our finding should be confirmed clinically
by follow up for tumor recurrence. Further study should
address on insight into the mechanism regulated by endo-
can and other growth/vascular factors, cytokines, signal
factors in tumor epithelium and endothelial cells has the
potential to further the development of invasive pituitary
tumor therapies.
Conclusion
We found that endocan protein expression was mainly
detected in the tumor cells of pituitary adenomas and was
significantly correlated with Knosp grades when compared
to that of CD34/CD105-positive MVDs. These results
suggested that endocan-mediated tumor progression occurs
through an uncertain mechanism, but is likely dependent on
endocan binding to or interacting with multiple molecules,
rather than directly promoting angiogenesis. Endocan
overexpression strongly correlated with the invasive
behavior of pituitary adenomas, which have less angio-
genesis than normal pituitary tissues.
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